Affimed N.V.

Affimed N.V.: Proprietary ROCK® platform enabling generation of multi-specific antibodies is basis for its collaboration with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics. Pipeline includes NK cell engager AFM13 (CD30/CD16A) to enter Ph 2 registration study in CD30-positive PTCL and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. IND cleared for AFM24, the company’s innate cell engager that targets EGFR-expressing solid tumors.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, USA
Clinical Stage
Phase l or ll
Disease Space
Hematology, Immuno-Oncology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Profiles:
Address:
Im Neuenheimer Feld 582
Heidelberg, Baden-Wurttemberg 69120
Germany

Company Participants at Solebury Trout Virtual Management Access Event 2021

Adi Hoess, Ph.D.
Affimed N.V., Chief Executive Officer
Dr Hoess joined Affimed in October 2010 as Chief Commercial Officer and since September 2011 leads the company as CEO. He has more than 18 years professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A. Prior to Affimed, Dr. Hoess was Chief Commercial Officer at Jerini AG and CEO of Jenowis AG. At Jerini AG he was responsible for BD and the market introduction of Firazyr. He also played a major role in the M&A process of Jerini AG with Shire. From 2000 - 2002 Dr. Hoess was General Manager and VP of the Molecular Medicine Division at Carl-Zeiss in Jena. Dr. Hoess began his professional career in 1993 at MorphoSys as scientist. In 1997 he became Director of BD and in 1999, VP of Licensing and BD. Dr. Hoess received his PhD in chemistry and biochemistry from the University of Munich in 1991, and he also received an M.D. from the Technical University (TU) of Munich in 1997. From 1991 until 1993 Dr Hoess worked as a post doc at the Dana-Faber Cancer Institute at the Harvard Medical School in Boston, USA.
Alexander Fudukidis
Affimed N.V., Head of US IR
Since May 2020 Alexander has been with Affimed, serving as Head of Investor Relations. Previously he was VP at Syneos Health for 9 months. Before that he was with Russo Partners for over 3 years, serving as VP and Head of Investor Relations. Alexander has further experience in the field of Investor Relations from his time in China 2001-2015. Alexander holds a MS in Finance as well as a BA in Finance and Law from Baruch College.
Angus Smith
Affimed N.V., CFO
Mr. Smith joined Affimed in July 2020 as Chief Financial Officer. Previously, he was Chief Financial Officer at Rockwell Medical, Inc., a biopharmaceutical company developing and commercializing anemia therapies. He has broad biopharmaceutical industry experience including financial strategy, capital markets, business development and operations. Prior to Rockwell, Mr. Smith served as Senior Vice President, Chief Business Officer and Principal Financial Officer at Pernix Therapeutics, a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs. Mr. Smith began his career in healthcare investment banking, having served as Director in the Healthcare Investment Banking Group at Cantor Fitzgerald in New York, NY. During his nearly decade-long investment banking tenure, he focused on strategic and financial advice for life science and healthcare companies. He has worked on a substantial number of transactions across the healthcare sector with an aggregate transaction value of more than billion. Mr. Smith holds a Bachelor of Arts in Mathematical Economics from Colgate University in Hamilton, NY.
Nathalie Knappe
Affimed N.V., IR

Lead Programs

AFM13

Disease Target CD30 Immune Cell Target CD16A

Indication Phase
Hodgkin lymphoma + PD-1 1
Hodgkin lymphoma 2
Hodgkin lymphoma + adoptive NK cells Pre-clinical
CD30-positive lymphoma 2

AFM24

Disease Target EGFRwt Immune Cell Target CD16A

Indication Phase
Solid tumors Pre-clinical

Top 10 Holders of Affimed N.V.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
NEA Management Co. 8.04 6,126,488 39.94 13F 9/30/20
683 Capital Management LLC 4.79 3,650,000 23.80 13F 9/30/20
BlackRock Fund Advisors 4.41 3,360,265 21.91 13F 9/30/20
Citadel LP 4.16 3,173,215 20.69 13F 9/30/20
Millennium Management LLC 2.96 2,255,617 14.71 Stakes 12/31/20
Bain Capital Public Equity Management II LLC 2.82 2,148,513 14.01 13F 9/30/20
Point72 Asset Management LP (Old) 2.62 2,000,000 13.04 13F 9/30/20
Acadian Asset Management LLC 2.49 1,900,379 12.39 13F 9/30/20
State Street Corp. 2.08 1,589,594 10.36 13F 9/30/20
Eversept Partners LP 1.63 1,245,458 8.12 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.